FOXE1 and cancer: Overall, the landscape emerging from the literature strongly indicates that either due to genetic variants or to other still unidentified regulators, the expression level of FOXE1 is a possible determinant underlying the susceptibility to PTC and/or other cancer phenotypes [27].